JP2008508864A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508864A5
JP2008508864A5 JP2007518205A JP2007518205A JP2008508864A5 JP 2008508864 A5 JP2008508864 A5 JP 2008508864A5 JP 2007518205 A JP2007518205 A JP 2007518205A JP 2007518205 A JP2007518205 A JP 2007518205A JP 2008508864 A5 JP2008508864 A5 JP 2008508864A5
Authority
JP
Japan
Prior art keywords
chain variable
variable region
seq
human
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007518205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508864A (ja
JP5160887B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/021951 external-priority patent/WO2006002177A2/en
Publication of JP2008508864A publication Critical patent/JP2008508864A/ja
Publication of JP2008508864A5 publication Critical patent/JP2008508864A5/ja
Application granted granted Critical
Publication of JP5160887B2 publication Critical patent/JP5160887B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007518205A 2004-06-21 2005-06-20 インターフェロンアルファレセプター1抗体及びその使用法 Expired - Lifetime JP5160887B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58174704P 2004-06-21 2004-06-21
US60/581,747 2004-06-21
PCT/US2005/021951 WO2006002177A2 (en) 2004-06-21 2005-06-20 Interferon alpha receptor 1 antibodies and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012217849A Division JP5899540B2 (ja) 2004-06-21 2012-09-28 インターフェロンアルファレセプター1抗体及びその使用法

Publications (3)

Publication Number Publication Date
JP2008508864A JP2008508864A (ja) 2008-03-27
JP2008508864A5 true JP2008508864A5 (enExample) 2008-08-07
JP5160887B2 JP5160887B2 (ja) 2013-03-13

Family

ID=35782299

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007518205A Expired - Lifetime JP5160887B2 (ja) 2004-06-21 2005-06-20 インターフェロンアルファレセプター1抗体及びその使用法
JP2012217849A Expired - Lifetime JP5899540B2 (ja) 2004-06-21 2012-09-28 インターフェロンアルファレセプター1抗体及びその使用法
JP2015135415A Pending JP2015172088A (ja) 2004-06-21 2015-07-06 インターフェロンアルファレセプター1抗体及びその使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012217849A Expired - Lifetime JP5899540B2 (ja) 2004-06-21 2012-09-28 インターフェロンアルファレセプター1抗体及びその使用法
JP2015135415A Pending JP2015172088A (ja) 2004-06-21 2015-07-06 インターフェロンアルファレセプター1抗体及びその使用法

Country Status (18)

Country Link
US (6) US7662381B2 (enExample)
EP (2) EP1781705B1 (enExample)
JP (3) JP5160887B2 (enExample)
KR (4) KR101541658B1 (enExample)
CN (3) CN102863532A (enExample)
AU (1) AU2005258077C1 (enExample)
CA (1) CA2570823C (enExample)
CY (2) CY1115875T1 (enExample)
DK (2) DK1781705T3 (enExample)
ES (2) ES2526194T3 (enExample)
HU (1) HUE035082T2 (enExample)
LT (1) LT2662390T (enExample)
MX (1) MX2007000023A (enExample)
PL (2) PL2662390T3 (enExample)
PT (2) PT1781705E (enExample)
RU (2) RU2600884C2 (enExample)
SI (2) SI1781705T1 (enExample)
WO (1) WO2006002177A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1631312B1 (en) * 2003-04-23 2008-09-10 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
EP1781705B1 (en) 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
JPWO2006054748A1 (ja) * 2004-11-22 2008-06-05 Sbiバイオテック株式会社 腎炎の治療剤
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Cd19抗体およびその使用法
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
WO2008070135A2 (en) * 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
CL2007003622A1 (es) * 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN101909444B (zh) * 2007-11-05 2013-09-18 米迪缪尼有限公司 硬皮病治疗方法
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
EP2352759B1 (en) 2008-07-16 2017-11-01 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
JP5475774B2 (ja) * 2008-07-16 2014-04-16 インスティテュート フォー リサーチ イン バイオメディシン ヒトサイトメガロウイルス中和抗体およびその使用
CN101580546B (zh) * 2009-06-04 2011-09-14 中国疾病预防控制中心病毒病预防控制所 人源抗人干扰素α抗体及其应用
ES2613055T3 (es) 2009-09-03 2017-05-22 Medimmune, Llc Diagnóstico de interferón de tipo 1
US9493570B2 (en) * 2012-06-13 2016-11-15 Medimmune, Llc Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
US20160003850A1 (en) * 2013-02-26 2016-01-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105358575B (zh) * 2013-03-15 2020-09-22 詹森生物科技公司 干扰素α和ω抗体拮抗剂
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015061526A1 (en) * 2013-10-25 2015-04-30 Medimmune, Llc Antibody purification
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека
US10329258B2 (en) 2015-04-30 2019-06-25 University Of Washington CGAS in systemic lupus erythematosus (SLE)
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
CN108409862B (zh) 2016-07-14 2021-07-13 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
WO2018136625A2 (en) * 2017-01-20 2018-07-26 Children's Medical Center Corporation Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss
US20200031943A1 (en) 2017-03-21 2020-01-30 Austrianni Gmbh Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗PHF-Tau抗體及其用途
JP7406254B2 (ja) * 2018-06-01 2023-12-27 アイエルシー セラピューティクス リミテッド 疾患の治療に関する組成物および方法
US11059897B2 (en) 2018-09-18 2021-07-13 I-Mab Biopharma Us Limited Anti-IFNAR1 antibodies for treating autoimmune diseases
CN116333132A (zh) * 2019-01-31 2023-06-27 广东旋玉健康生物科技有限公司 新型抗ifnar1抗体
KR20210131354A (ko) 2019-02-15 2021-11-02 아스트라제네카 아베 I형 인터페론-매개 장애
KR102766960B1 (ko) 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
CA3174858A1 (en) * 2020-04-20 2021-10-28 Juho JALKANEN Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitor
AU2021279277A1 (en) 2020-05-29 2023-02-02 Astrazeneca Ab Treatment of cardiometabolic disease with inhibitors of type I interferon signalling
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
US20240327529A1 (en) 2020-11-18 2024-10-03 Astrazeneca Ab Steroid sparing
LT4114465T (lt) 2021-04-23 2023-11-10 Astrazeneca Ab Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai
US20250002590A1 (en) 2021-04-23 2025-01-02 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
JP2024519196A (ja) * 2021-04-23 2024-05-09 アストラゼネカ・アクチエボラーグ 皮膚エリテマトーデスの処置
JP2024516886A (ja) 2021-05-12 2024-04-17 アストラゼネカ・アクチエボラーグ 全身性エリテマトーデス患者における1型インターフェロン受容体阻害剤のステロイド節約
CN113278071B (zh) * 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
EP4377349A1 (en) 2021-07-27 2024-06-05 Astrazeneca AB Treatment of lupus
CA3233069A1 (en) 2021-10-04 2023-04-13 Astrazeneca Ab Treatment of lupus
CN119604764A (zh) 2022-08-29 2025-03-11 江苏恒瑞医药股份有限公司 免疫调节剂的筛选和制备方法
TW202411257A (zh) 2022-08-29 2024-03-16 大陸商江蘇恆瑞醫藥股份有限公司 包含taci多肽的融合蛋白及其用途
CN120344259A (zh) * 2022-10-13 2025-07-18 阿斯利康(瑞典)有限公司 狼疮的治疗
CN121127499A (zh) 2023-05-19 2025-12-12 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5516515A (en) 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL88377A (en) 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
FR2653445B1 (fr) 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
WO1993004699A1 (en) 1991-08-30 1993-03-18 Genentech, Inc. Therapeutic method for iddm
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0563487A1 (en) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5821078A (en) 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
AU678429B2 (en) 1992-12-29 1997-05-29 Genentech Inc. Treatment of inflammatory bowel disease with IFN-gamma inhibitors
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
CA2171955A1 (en) 1993-09-17 1995-03-23 Michael G. Tovey Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
AU1289595A (en) 1993-11-15 1995-06-06 Cell Therapeutics, Inc. Method for selectively inhibiting il-2 signal transduction
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7285526B2 (en) 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
IL118096A0 (en) 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
JP4292262B2 (ja) 1998-01-30 2009-07-08 アラタイン セラピューティクス, エルエルシー 予後アレルギー試験または予後炎症試験
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
AUPP670698A0 (en) 1998-10-23 1998-11-19 Monash University A method of regulation
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
HK1049014A1 (zh) 1999-07-29 2003-04-25 Medarex, Inc. 抗her2/neu的人类单克隆抗体
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
GB0001712D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
IT1321086B1 (it) 2000-11-24 2003-12-30 Cselt Centro Studi Lab Telecom Sistema e metodo per individuare la posizione di apparecchiaturemobili
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
EP2236156A3 (en) 2001-01-09 2011-01-05 Baylor Research Institute Methods for treating and diagnosing Psoriasis
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
JP4676333B2 (ja) 2003-04-02 2011-04-27 株式会社リケン シールリング
MXPA05011406A (es) * 2003-04-23 2005-12-12 Medarex Inc Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1).
EP1631312B1 (en) 2003-04-23 2008-09-10 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
DK1711207T3 (da) 2003-12-10 2013-03-11 Medarex Inc Interferon-alpha-antistoffer og anvendelse heraf
EP1781705B1 (en) * 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
HUE028958T2 (en) * 2008-02-08 2017-01-30 Medimmune Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US9493570B2 (en) * 2012-06-13 2016-11-15 Medimmune, Llc Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
LT4114465T (lt) * 2021-04-23 2023-11-10 Astrazeneca Ab Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai

Similar Documents

Publication Publication Date Title
JP2008508864A5 (enExample)
RU2007102079A (ru) Антитела рецептора интерферона альфа и их применение
JP4294596B2 (ja) 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
Schmid et al. Advances in antibody engineering for rheumatic diseases
RU2766094C2 (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
JP2010511388A5 (enExample)
JP2010500005A5 (enExample)
JP2012501670A5 (enExample)
JP2009502171A5 (enExample)
WO2014206107A1 (zh) 抗pd-1抗体及其应用
RU2009128064A (ru) Антитела к cd44
JP2007514419A5 (enExample)
JP2015519375A5 (enExample)
JP2011509245A5 (enExample)
CN109022465A (zh) 多肽构建体及其用途
WO2016197497A1 (zh) 一种抗pd-1的单克隆抗体及其获得方法
JP2015504896A5 (enExample)
JP2006089494A (ja) I型インターフェロンに対する中和活性を有するインターフェロン受容体に対するモノクローナル抗体
JPH06500229A (ja) 擬人化cdr移植抗icam―1抗体、その生産方法及びその使用
CN114736291B (zh) 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
CN117279950B (zh) 一种靶向il-18bp的抗体及其应用
Shinde et al. Polyvalency: an emerging trend in the development of clinical antibodies
Samuel et al. Isolation of human single chain variable fragment antibodies against specific sperm antigens for immunocontraceptive development
CN110114370A (zh) 能够与人白细胞介素-6受体结合的抗体或其抗原结合片段
Araki et al. A Brief Chronicle of Antibody Research and Technological Advances